Catabasis shares rocket up on Duchenne pact with Sarepta; bluebird whistles up a TCR deal with Medigene
The long lineup of new biotech deals we’re seeing today continues in the Protocols section, with more pacts from Sarepta and bluebird.
Shares of Catabasis rocketed up 56% this morning on news of a new partnership. Fresh from winning the year’s most controversial FDA approval, Sarepta $SRPT is partnering with Catabasis on a combo drug for Duchenne muscular dystrophy. Catabasis $CATB will pair its preclinical oral NF-kB inhibition program with one of Sarepta’s exon-skipping programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.